ENGLE J MELVILLE
Known title: CEO and ChairmanCIK: 0001461906
ENGLE J MELVILLE's purchase track record
ENGLE J MELVILLE has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/24/2022 | AGPU | $59K | +20.1% | -10.8% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AGPU | ▲ Buy | Grant | 213,300 | $0 | 11/1/2022 | View on chart |
| AGPU | ▲ Buy | Open Market | 159,500 | $59K | 5/24/2022 | View on chart |
| AGPU | ▲ Buy | Grant | 20,428 | $0 | 1/4/2022 | View on chart |
| AGPU | ▲ Buy | Grant | 4,512 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Axe Compute Signs $266M in AI Contracts, Exits Cancer Business
Axe Compute has secured over $266 million in new AI infrastructure contracts since mid-August. The company is also selling its cancer business to fully transition into an AI-focused entity. These moves mark a significant strategic shift for the stock, which trades with high beta and has a wide 52-week range.
Axe Compute Signs $266M in AI Contracts, Exits Cancer Business. Axe Compute has secured over $266 million in new AI infrastructure contracts since mid-August. The company is also selling its cancer business to fully transition into an AI-focused entity. These moves mark a significant strategic shift for the stock, which trades with high beta and has a wide 52-week range.